Scholar

Kathryn A. Phillips

H-index: 42
Economics 44%
Biology 30%
kathrynp-phd.bsky.social
2 leading experts on scientific publication & former Editors-in-Chief @JAMA published commentary in #HAScholar @Health_Affairs on Administration's focus on “gold standard science” – its opportunities but also its challenges. academic.oup.com/healthaffair...
Validate User
academic.oup.com
kathrynp-phd.bsky.social
Drummond was great mentor to me...continuing his efforts now! Commentary from 2 experts on scientific publication & former Editors-in-Chief @JAMA in #HAScholar @Health_Affairs on Administration's focus on “gold standard science” – opportunities but also challenges. academic.oup.com/healthaffair...
kathrynp-phd.bsky.social
Thrilled to publish this in #HAScholar @ Health Affairs. "So much is changing in the drug approval and pricing space, and in order to ensure affordability for patients and society,
policymakers should pay close attention to the merits of a U.S.-based value assessment approach
kathrynp-phd.bsky.social
Many questions about Pfizer deal with Trump Administration to avoid tariffs. Why does the federal government need to become a drug marketer? Doesn’t it already do enough not very well? www.wsj.com/opinion/dona... via @WSJopinion
Opinion | America’s Pharmacist in Chief
The President becomes a drug marketer, while Pfizer gets a tariff break.
www.wsj.com
kathrynp-phd.bsky.social
Here's where behavioral economics and the great insights of Daniel Kahneman (who I learned so much from when I took his class at UC-Berkeley) could be useful....
robcaliff.bsky.social
An opinion about the need to better understand the framing and decision making that impacts so much of preventive public health--"habits" and inconveniences to prevent low probability, but high impact future events in return for some up front risk.

substack.com/@robcaliff27...
Interventions for Low-Probability Events
Recently, I have been struggling to understand why so few people have taken the updated COVID booster when the benefit-risk calculation seems so straightforward.
substack.com
kathrynp-phd.bsky.social
Nicely nuanced discussion about balancing risk/benefit. This struck me “COVID vaccine decision is qualitatively different than vaccines such as polio... because the vaccines prevent transmission. With COVID vaccination, the benefit is to the individual, with modest effects on transmission.”
kathrynp-phd.bsky.social
On the rare day that it's 85 degrees in San Francisco, one must eat soft serve on the Bay!
robcaliff.bsky.social
An opinion about the need to better understand the framing and decision making that impacts so much of preventive public health--"habits" and inconveniences to prevent low probability, but high impact future events in return for some up front risk.

substack.com/@robcaliff27...
Interventions for Low-Probability Events
Recently, I have been struggling to understand why so few people have taken the updated COVID booster when the benefit-risk calculation seems so straightforward.
substack.com
kathrynp-phd.bsky.social
Interesting book about my alma mater @UCBerkeley's evolution from early backlash against corporate collaborations to current exuberance for entrepreneurs and startups. iande.berkeley.edu/startupcampus
Startup Campus: How UC Berkeley Became an Unexpected Leader in Entrepreneurship and Startups | Innovation & Entrepreneurship
iande.berkeley.edu
kathrynp-phd.bsky.social
Sorry to hear that Drummond Rennie passed away. When he was @JAMA_current Deputy Editor based in SF, I benefited so much from his mentorship. He did not mince words in telling me when my work needed improvement - and indeed, he was right.

References

Fields & subjects

Updated 1m